RICK DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages RCI Hospitality Holdings, Inc. Investors to Secure Counsel Before Important November 20 Deadline in Securities Class Action First Filed by the Firm - RICKNovember 17, 2025 5:01 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RCI Hospitality Holdings, Inc. (NASDAQ: RICK) between December 15, 2021 a ...

Barksdale Resources Releases Spring 2025 AssaysProvides Updates on Phase ll Drilling and Company ActivitiesNovember 17, 2025 5:00 PM EST | Source: Barksdale Resources Corp.Vancouver, British Columbia--(Newsfile Corp. - November 17, 2025) - Barksdale Resources Corp. (TSXV: BRO) (OTCQB: BRKCF) (FSE: 2NZ) ("Barksdale" or the "Company") has released assays from the Company's Spring 2025 drill program with encouraging results and copper grades and provides an update on the Phase ll drill plan to br ...

Core Viewpoint - Galleon Gold Corp. has opted to fulfill its interest payment obligations on convertible debentures by issuing common shares instead of cash, which is subject to approval from the TSX Venture Exchange [1][3]. Group 1: Convertible Debentures and Interest Payments - The company issued convertible debentures on April 12, 2024, April 19, 2024, and April 29, 2024, and has decided to pay accrued interest by issuing common shares [1][2]. - A total of $87,012.74 in interest will be paid by issuing 134,998 common shares for the interest payments due on April 12, 2025, and April 19, 2025 [3]. - An additional $45,211.64 in interest will be satisfied by issuing 67,637 common shares for the interest payment due on April 29, 2025 [4]. Group 2: Related Party Transactions - Certain officers and insiders of the company hold the convertible debentures, making the interest payment a "related party transaction" under Multilateral Instrument 61-101 [5]. - The interest payment is exempt from minority approval and formal valuation requirements as neither the fair market value of the debt nor the shares to be issued exceeds 25% of the company's market capitalization [5]. Group 3: Company Overview - Galleon Gold is focused on the West Cache Gold Project in Timmins, Ontario, which is located near significant mining operations [6]. - The company is preparing for its first test mining at West Cache, with an 86,500-tonne underground bulk sample aimed at providing data for feasibility studies [6]. - The strategy of Galleon Gold includes systematically derisking the project while pursuing grassroots exploration to enhance asset value [6].

Core Insights - Ardent Health, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company reported a $43 million reduction in revenue and a $54 million increase in professional liability reserves in its Q3 2025 financial results [2] - Following the financial disclosures, Ardent's stock experienced a significant decline during pre-market trading [3] Financial Performance - Ardent Health disclosed a $43 million decrease in revenue due to changes in accounting estimates regarding accounts receivable [2] - The company also announced a $54 million increase in professional liability reserves related to claims in New Mexico [2] Market Reaction - The stock price of Ardent Health fell significantly in pre-market trading on November 13, 2025, following the release of its financial results [3]

Core Insights - Bitdeer Technologies Group is under investigation for possible violations of federal securities laws by Levi & Korsinsky [1] - The company reported a significant earnings miss for Q3 2025, with an earnings per share of -$1.28 compared to the consensus estimate of -$0.22 [2] - Bitdeer announced delays in the development of its next-generation Seal 04 ASIC chip, which may impact future performance [2] - Following the earnings report and news of the delays, Bitdeer's stock price dropped over 14% on November 11, 2025 [2] Company Performance - Bitdeer reported unaudited financial results for Q3 2025, highlighting a substantial loss in earnings per share [2] - The company faced significant operational challenges, particularly with the delay in the development of its ASIC chip [2] Market Reaction - The stock price of Bitdeer fell by more than 14% in response to the negative earnings report and the announcement of delays [2]

Core Insights - Dr. Teoh Pui Pui, co-founder and co-CEO of Mobile-health Network Solutions, has increased her equity stake in the company through an open market purchase, reflecting her confidence in the company's growth prospects [1][3] Company Overview - Mobile-health Network Solutions is a leading AI-powered digital health platform based in Singapore, with operations in Southeast Asia and plans to expand into the US [5] - The company offers telemedicine services, AI-driven health tools, and virtual clinic infrastructure aimed at enhancing healthcare accessibility and intelligence [5] Shareholder Activity - On November 5, 2025, Dr. Teoh purchased 0.4% of the outstanding Class A Ordinary Shares for approximately US$8,751.32, increasing her total ownership to 110,596 shares, which is about 9.5% of the company's outstanding shares as of November 14, 2025 [2][3]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The deadline to move the court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is urging investors of Quanex Building Products Corporation to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to misleading statements made during the Class Period from December 12, 2024, to September 5, 2025 [1][2]. Group 1: Legal Action Details - Investors who purchased Quanex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Quanex made false and misleading statements regarding its tooling and equipment maintenance procedures at its Tyman Mexico facility, which were significantly underinvested [5]. - It is claimed that the conditions of the tooling and equipment had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [5]. - The lawsuit asserts that Quanex had previously identified these issues, and the positive statements made by the defendants about the company's business and prospects were materially misleading [5].

Core Insights - Gorilla Technology Group Inc. has secured a $1.4 billion AI data center mandate, contributing to a total advanced AI and GPU infrastructure pipeline exceeding $7 billion, with phased implementation starting in early 2026 [1][10][12] Financial Performance - Record revenue growth was reported for Q3 2025, with revenue reaching $26.5 million, a 32% increase from $20.1 million in Q3 2024, driven by AI infrastructure and public safety projects across multiple regions [2][8] - The company achieved an operating income of approximately $0.4 million in Q3 2025, a significant turnaround from an operating loss of $6.0 million in Q3 2024, reflecting improved efficiency and disciplined operating expenses [3][8] - EBITDA for Q3 2025 was $0.8 million, compared to a loss of $5.6 million in Q3 2024, while net loss was nearly breakeven at $0.03 million, a substantial improvement from a loss of $7.8 million in the prior year [4][8] Cash and Debt Management - As of September 30, 2025, total debt decreased by 30% to $15.1 million from $21.4 million at the end of 2024, while unrestricted cash increased to $110.2 million, marking a 408% rise from $21.7 million at the end of 2024 [5][8][14] - The company is focused on maximizing working capital flexibility to support existing contracts and client pipeline conversion without straining the balance sheet [5][14] Earnings Per Share - Basic and diluted EPS were approximately breakeven for Q3 2025, with adjusted basic EPS at $0.26 and adjusted diluted EPS at $0.24 [6][8] Project Updates - Gorilla is actively executing 5G and AI infrastructure projects in Southeast Asia, with deployment activities accelerating, while projects in the MENA region are entering the final execution phase [9][10] Financial Outlook - For full year 2026, Gorilla expects revenue between $137 million and $200 million, supported by the initial phase of the $1.4 billion AI data center project and two major law enforcement contracts [10][11] - The company maintains its 2025 revenue guidance of $100 million to $110 million, with adjusted EBITDA expected between $20 million and $25 million [13][10]

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, Incorporated, alleging securities fraud that affected shareholders between December 27, 2023, and May 6, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically indicating expected FDA approval in the second half of 2025 based on a September 26, 2025 PDUFA date [3]. - The complaint highlights that the company failed to disclose significant risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [3]. - During an earnings call on May 6, 2025, it was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, indicating awareness of potential requirements and misleading investors about the regulatory timeline [4]. Group 2: Impact on Shareholders - As a result of the defendants' misleading statements, shareholders purchased Cytokinetics' common stock at artificially inflated prices and incurred significant losses when the truth about the regulatory process was disclosed [5]. - Shareholders who suffered losses during the relevant time frame are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [6]. Group 3: Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, has a strong track record of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [7].